ABT19 1628047-87-9 CAS NO.1628047-87-9

Min.Order: 1 Gram
Payment Terms: T/T

Product Details

Keywords

supplier Custom synthesis
manufacturer low price
high quality

Quick Details

ProName: ABT19 1628047-87-9
CasNo: 1628047-87-9
Appearance: white powder
Application: Use for API ,parmaceutical intermediat...
DeliveryTime: In stock
PackAge: brown vial + Aluminum foil bag +box(Pa...
Port: jinan
ProductionCapacity: 1 Gram/Day
Purity: 95% min
Storage: Store in dry/sealed/low temperature
Transportation: by sea by air
LimitNum: 1 Gram

Superiority

Known for its best quality and competitve price, this chemicals we offered is widely appreciated by our customers.

1) All Purity≥95%

2) We are manufacturer and can provide high quality products with factory price.

2, Fast and safe delivery

2) Secure and discreet shipment.Various transportation methods for your choice.

Details

Our Company

Shandong Bolode Bio-Technology Co., Ltd is a professional company which engaged in the R&D and manufacture of Pharmaceuticals intermediates and Chemical Raw materials. The company is located in Jinan, the capital of Shandong Province. With the advanced equipment, quality management and many years producing experience, The company has completed quality ass urance system and strong research and innovation ability.

We are a professional manufacturer and supplier for Pharmaceutical impurity ,API,also we can do custom synthesis for Impurities and new compounds .

We serve drug research both for domestic and worldwide . Now more than 400 kinds of impurities projects ,thousands of impurities can be supplied , and have exported to India , Europe and USA .

Purity : 95%+ min

Supply COA , HPLC ,HNMR ,MASS

Direct manufacturers with high quality and best price !

ABT-199 is a new type of anti-cancer drug, a Bcl-2 inhibitor, developed by the American pharmaceutical company AbbVie (AbbVie), which can effectively resist cancer, and will produce less than current drugs The side effects of this study were mainly completed by researchers in the United States and Australia, and the relevant research results were published in the international journal Nature Medicine.

The difference from ordinary cancer drugs is that this drug named ABT-199 acts as a treatment for cancer by attacking an important protein called BCL-2. BCL-2 is one of the first members of the BCL-2 protein family discovered to regulate cell death. It is associated with many types of cancer, as well as some mental illnesses and autoimmune diseases. In cancer, it is thought that it acts as a suppressor that can help cancer cells resist cancer treatment drugs.

In the treatment of cancer, cancer cells can use the pro-survival protein BCL-2 to inhibit the therapeutic effect of traditional chemotherapy, which often causes headaches for clinicians. It is precisely because cancer cells can use the pro-survival protein BCL-2 to inhibit the therapeutic effect of traditional chemotherapy, which makes clinicians have to repeatedly increase the dose, which leads to chemotherapy side effects such as nausea and hair loss.

The emergence of ABT-199 as a drug that can eliminate and reduce BCL-2 in cancer cells has made many clinicians see the dawn of cancer treatment. As a new type of anticancer drug, ABT-199 can inhibit the growth of BCL-2 without affecting BCL-XL, a protein necessary for platelet formation. The overcoming of this problem is worth cheering in the history of tumor treatment.

ABT19 1628047-87-9 CAS NO.1628047-87-9

Keywords

Quick Details

Superiority

Details

Other products of this supplier